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Abstract 
Background: The expansion and metastasis of colorectal cancers are closely associated with the dynamic growth 
of cancer stem cells (CSCs). This study aimed to explore the possible effect of LXR (a regulator of glycolysis and lipid 
hemostasis) in the tumorgenicity of human colorectal CD133 cells.
Methods: Human HT‑29  CD133+ cells were enriched by MACS and incubated with LXR agonist (T0901317) and 
antagonist (SR9243) for 72 h. Cell survival was evaluated using MTT assay and flow cytometric analysis of Annexin‑V. 
The proliferation rate was measured by monitoring Ki‑67 positive cells using IF imaging. The modulation of LXR was 
studied by monitoring the activity of all factors related to ABC transporters using real‑time PCR assay and western 
blotting. Protein levels of metabolic enzymes such as PFKFB3, GSK3β, FASN, and SCD were also investigated upon 
treatment of CSCs with LXR modulators. The migration of CSCs was monitored after being exposed to LXR agonist 
using scratch and Transwell insert assays. The efflux capacity was measured using hypo‑osmotic conditions. The intra‑
cellular content of reactive oxygen species was studied by DCFH‑DA staining.
Results: Data showed incubation of CSCs with T0901317 and SR9243 reduced the viability of CD133 cells in a 
dose‑dependent manner compared to the control group. The activation of LXR up‑regulated the expression and 
protein levels of ABC transporters (ABCA1, ABCG5, and ABCG8) compared to the non‑treated cells (p < 0.05). Despite 
these effects, LXR activation suppressed the proliferation, clonogenicity, and migration of CD133 cells, and increased 
hypo‑osmotic fragility (p < 0.05). We also showed that SR9243 inhibited the proliferation and clonogenicity of CD133 
cells through down‑regulating metabolic enzymes PFKFB3, GSK3β, FASN, and SCD as compared with the control cells 
(p < 0.05). Intracellular ROS levels were increased after the inhibition of LXR by SR9243 (p < 0.05).
Calling attention, both T0901317 and SR9243 compounds induced apoptotic changes in cancer stem cells (p < 0.05).
Conclusions: The regulation of LXR activity can be considered as a selective targeting of survival, metabolism, and 
migration in CSCs to control the tumorigenesis and metastasis in patients with advanced colorectal cancers.
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Background
Colorectal cancer (CRC) is one of the most common 
malignancies in the world [1], and despite current devel-
opments in treatment and screening methods, today 
nearly 50 % of patients with advanced CRC experience 
tumor relapse and metastasis [2]. The failure of CRC 
therapy could be explained by the presence of the rare 
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population of CSCs which causes drug resistance, tum-
origenesis, recurrence, and metastasis [3]. These cells 
could need on-demand energy for bioactivity and dif-
ferentiation during the cancer stroma [4]. It has been 
shown that CRC development is affected by a high-fat 
diet or CHOL consumption [1, 5]. CHOL is a sterol that 
has proliferative effects on cells via supporting the cell 
membrane integrity and CHOL-rich membranes (or lipid 
rafts) formation [5]. For example, the CHOL content acts 
as putative mitogen through SREBP-2 (sterol regulatory 
element-binding protein) expression that promotes the 
proliferation and tumorigenesis of intestinal stem cells 
[6]. It has also shown that the lipid raft membrane-local-
ized matrix metalloproteinase-2 induces the migration of 
stem cells through degrading the ECM and activation of 
matrix metalloproteinase-9 [7].
In normal cells, ABCs had the potential to efflux the 
intracellular CHOL to the ECM. Notably, it has been elu-
cidated that these proteins have been suppressed during 
pathological cancer conditions [8]. LXRs are touted as the 
members of the nuclear receptor and form an activated 
heterodimer with RXRs to binds to LXR-responsive ele-
ments in DNA. LXRs could modify the transcription of 
target genes participating in tumor cell survival, metabo-
lism, and migration [9]. LXR regulates elevated colon cel-
lular CHOL by disrupting the CHOL synthesis-related 
effector such as SREBP, and upregulation of the ABC 
efflux pumps expression [10]. While activation of LXRs 
signaling is well studied in various types of somatic can-
cer cells, the critical role of LXRs has not been addressed 
in the dynamic growth of CSCs. In addition to the vital 
role of LXR-related signaling in CSCs activity, the prolif-
eration of these cells is closely related to glycolytic path-
way-dependent for ATP generation.
Calling attention, increased aerobic glycolysis (termed 
also Warburg effect) is touted as de novo lipogen-
esis which sustains cell proliferation and protects CSCs 
against stresses [11]. Among the several enzymes, the 
PFKFB3, and GSK3β are critical key enzymes involved 
in the control of glycolysis [12–14]. The surplus metab-
olites produced by the aerobic glycolysis are integrated 
into lipogenesis and thus this phenomenon increases 
the expression of lipid metabolism enzymes [e.g., FASN 
and SCD1] to induce endogenous production of lipids 
in tumor cells [12–14]. Moreover, inactivation of LXRs 
can inhibit the Warburg effect and lipogenesis, promot-
ing apoptosis in somatic tumor cells [12]. To the best of 
our knowledge, there are few reports regarding the role 
of LXR-derived signaling pathways in the survival and 
dynamic growth of CSCs.
Commensurate with these descriptions, we investi-
gated the effect of LXR activation on the growth, prolif-
eration, and migration of HT-29-isolated CSCs in vitro. 
We further studied the inactivation of LXR on CR-CSCs 
glycolysis and lipid metabolism.
Materials and methods
Cell culture
HT-29 cell line was purchased from the National Cell 
Bank of Iran (NCBI; Pasteur Institute, Tehran), and cul-
tured in RPMI 1640 (Gibco, USA) medium supplemented 
with 10% v/v FBS (Gibco, USA), 100 IU/ml Penicillin, and 
100  µg/ml Streptomycin (Gibco, USA). To expand the 
cells, the culture flasks were maintained at a humidified 
atmosphere of 95% air and 5%  CO2 at 37  °C. Cells were 
sub-cultured at 70–80% confluence using 0.25% Trypsin-
EDTA (Gibco). In this study, HT-29 cells at passages 3–6 
were used for subsequent analyses.
Chemical and preparation procedure
In this study, we used T0901317 (TOCRIS) as an LXR 
agonist and SR9243 (TOCRIS, china) as a selective LXR 
antagonist to stimulate and inhibit LXR signaling path-
ways in the isolated CSCs. The chemicals were dissolved 
in DMSO (Merck, Germany) to prepare 0.2  M (50  mg/
ml) stock solutions.
Isolation of CSCs using MACS
In the current experiment, CSCs were enriched based on 
stemness surface marker CD133 using MSACS according 
to the manufacturer’s instruction. In short, the adherent 
HT-29 cells were detached using 0.25 % trypsin-EDTA, 
washed twice with PBS. The non-specific binding sites 
were blocked with 1 % BSA (Sigma-Aldrich). To isolate 
 CD133+ cells, cells (42 × 106) were incubated with 120 µl 
of microbeads against CD133 (Miltenyi Biotec., Ger-
many) at 4 °C for 20 minutes on a rotator. Thereafter, cells 
were washed with PBS containing 1 % BSA and passed 
through LS columns (Miltenyi Biotec., Germany). Soon 
after enrichment,  CD133+ cells were collected as primary 
CSCs for subsequent studies.
Characterization of isolated CSCs by flow cytometry
To confirm the purity of enriched CSCs, we performed 
flow cytometric analysis of CD133. The samples were 
washed twice with PBS and incubated with 10 µl of the 
FITC-conjugated anti-human CD133 antibody (Clone: 
AC133; Cat No. 130-113-673; Miltenyi Biotec) at 4 °C for 
30 minutes. Then, cells were washed twice with PBS and 
fixed with 4 % PFA solution. Cells were analyzed using a 
FACSCalibur flow cytometer (BD Bioscience, USA) and 
FlowJo software (version 7.6.1). The purity of cells was 
compared with control HT-29 cells before the MACS 
procedure.
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Cell viability assay
The effect of T0901317 and SR9243 were determined on 
CSC viability by a colorimetric assay using MTT (Sigma-
Aldrich, USA). Briefly, 1 × 104 CSCs resuspended in cul-
ture medium enriched with 2 % FBS, transferred onto 
each well of 96-well plates, and allowed reach 70–80% 
confluence. After 24 h, cells were exposed to various 
concentrations of T0901317 (5–200  µM) or SR9243 
(25–200 nM) for 24, 48, and 72 h. After completion of the 
treatment protocol, 20 µl of MTT (5 mg/ml) solution was 
added to each well and incubated for the next 4 h. There-
after, the culture medium was removed and replaced with 
200 µl DMSO solution. Finally, the absorbance value was 
measured at 630  nm using a microplate reader (BioTeK 
Instruments, USA). Cell viability  (IC50) was determined 
for each agent by calculating the slope and intercept of 
different concentrations.
Real‐time PCR assay
Total RNA was extracted using RNA X plus solution 
(CinnaGen, Iran) according to the manufacturer’s pro-
cedure. The extracted RNA was reverse-transcribed into 
cDNA by a reverse transcription Kit (Bioneer, Korea). 
Real-time PCR analysis was performed using QuantiTect 
SYRB Green dye (TaKaRa, Japan) and Corbett Rotor-
Gene™ 6000 HRM system. Primer sequences were listed 
in Table 1. The expression levels of each gene were ana-
lyzed by Pfafl methods with normalization to the house-
keeping gene, GAPDH. Three sets of experiments were 
conducted.
  Western blotting
Following the completion of cell treatment with 
T0901317 and SR9243, CSCs were lysed in a protein 
extraction buffer composed of 25  mm HEPES, 1% Tri-
ton X-100, 2  mM EDTA, 0.1  M NaCl, 25  mM NaF, 
1  mM Sodium Orthovanadate, and protease cocktail 
inhibitor (Roche) on ice for 30 minutes. Cell lysates were 
centrifuged at 12,000  g for 20 minutes at 4  °C. Then, 
the total protein concentration of supernatants was 
measured using Nanodrop®. The samples were electro-
phoresed by 12% SDS-PAGE and transferred to PVDF 
membrane. A 5% skim milk solution was used to block 
non-specific binding sites. In this study, membranes 
were incubated with antibodies against ABCA1, ABCG5, 
ABCG8, HIF1A-F, SCD1, FASN, GSK3β, PFKFB3, and 
LXRα/β (Santa Cruz Biotechnology, Santa Cruz, USA) 
at 4  °C overnight. An appropriate secondary HRP-con-
jugated antibody was applied (Santa Cruz Biotechnol-
ogy, Santa Cruz, USA) for 1 hour at room temperature. 
Finally, immunoreactive bands were detected by using 
ECL reagent (BioRad). The density of each band was 
determined using ImageJ software (version 1.4).
Cell swelling assay
To assess the possible malfunction of ABC transport-
ers after treatment with T0901317, CSCs were exposed 
to two distinct medium, including hypotonic (65% 
osmolality; 55.48 mM NaCl, 3.3 mM KCl, 1 mM  MgCl2, 
1.109 mM  CaCl2, 0.9 mM  MgCl2, 11.9 mM HEPES, and 
191.2  mM Mannitol) and isotonic conditions [15]. The 
normal culture medium was considered an isotonic con-
dition. In brief, 1 × 105 CSCs were plated in each well of 
6-well plates and incubated with 5 µM T0901317 for the 
next 24 h. After supernatant removal, adherent cells were 
washed twice with pre-warmed PBS and re-suspended in 
isotonic and hypotonic media. The diameter of 60 cells 
was recorded randomly 15, 30, and 45 min after being 
treated with the hypotonic condition. Finally, the aver-
age cell diameter was calculated by ImageJ software and 
compared to the control group.
Measuring CSC proliferation using IF staining
To this end, we monitored the expression of Ki67, a 
nuclear factor, using IF. About 1 × 104 CSCs were seeded 
in each well of 8-well Chamber Slides and treated with 
Table 1 Primer list
Gene Forward primer Reverse primer Tm (°C)
ABCA1 TTC CCG CAT TAT CTG GAA AGC CAA GGT CCA TTT CTT GGC TGT 57.9
ABCG8 AGC CTC CTT GCT AGA TGT GAT GTC TCT CGC ACA GTC AAG TTG 57.9
ABCG5 ACT GCT TCT CCT ACG TCC TG CTG TAG TTG CCA ATC AGT CGG 59.4
SCD1 TCT AGC TCC TAT ACC ACC ACCA TCG TCT CCA ACT TAT CTC CTCC 60.3
FASN AAG GAC CTG TCT AGG TTT GATGC TGG CTT CAT AGG TGA CTT CCA 60.6
GSK3β CCG ACT AAC ACC ACT GGA AGCT AGG ATG GTA GCC AGA GGT GGAT 59.8
PFKFB3 ATT GCG GTT TTC GAT GCC AC GCC ACA ACT GTA GGG TCG T 58.8
HIF1A-F ATC CAT GTG ACC ATG AGG AAATG TCG GCT AGT TAG GGT ACA CTTC 60.3
GAPDH GGA GCG AGA TCC CTC CAA AAT GGC TGT TGT CAT ACT TCT CATGG 59.8
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5 µM T0901317 for 48 h. Then, cells were fixed with 4% 
paraformaldehyde solution for 10 min, washed twice with 
PBS, and incubated with PE-conjugated anti- Ki67 for 
30 minutes at room temperature. Finally, the cells were 
examined using a fluorescent microscope (Olympus sys-
tem, Japan).
Clonogenic assay
The possible effect of LXR agonist and antagonist was 
investigated on the clonogenic capacity of CSCs after 
48 h. For this purpose, 3D soft agar including 1 % gelatin 
and 0.1 % agarose was prepared. CSCs were treated with 
T0901317 (5 and 10 µM) and SR9243 (60 and 120 nM) in 
two separate groups. 1 × 103 CSCs were mixed with 3 ml 
soft agar and poured in each well of 6-well plates. On day 
21, CSCs colonies were counted in 10 randomly selected 
magnification fields.
Migration and invasion assays
We monitored the CSCs migration rate using in vitro 
Transwell insert® and scratch assays after the modulation 
of LXR activity.
Transwell insert assay
Briefly, 2 × 104 CSCs were pretreated with 5  µM 
T09013174 in 200  µl serum-free RPMI-1640 medium 
and poured into polycarbonate inserts with an 8-µm 
pore size (SPL). In the lower chamber, we added 750 µl 
culture medium supplemented with 2 % FBS. After 48 h, 
the number of migrated CSCs was counted in random 
10 fields at the bottom surface of the insert membrane 
stained with Giemsa.
Invasion (scratch) assay
To this end, 1 × 106 CSCs were seeded in each well of a 
6-well plate and allowed to reach confluent monolayer 
cells and treated with 5 µM T0901317. The confluent cell 
layer was wounded by scratching with sterile 1000 µl dis-
posable blue pipette tips. After 24 h, the distance between 
scratch edges was measured calculated using ImageJ soft-
ware (NIH; Version 1.4).
Measurement of intracellular ROS
The evaluation ROS level was done using DCFH-DA 
staining. In brief, SR9243-treated CSCs were incubated 
with 10  µg/ml of DCFH-DA for 60 minutes. Thereaf-
ter, cells were trypsinized and washed twice with PBS. 
Finally, cells were visualized using fluorescence micros-
copy. The fluorescence intensity of the treatment group 
was compared to the non-treated control.
Apoptosis assay
The percent of apoptotic cells was determined after LXR 
inhibition/induction via flow cytometric analysis of 
Annexin V (Beyotime Biotechnology, Shanghai, China). 
After treatment with T0901317 and SR9243, cells were 
collected using an enzymatic solution. Cells were washed 
twice with PBS and resuspended in binding buffer (eBi-
oscience) at 4  °C for 20 min followed by incubation in 
10  µg/mL FITC-labeled Annexin V at 4  °C for 20–30 
min. The percent of apoptotic CSCs were determined 
using the BD FACSCalibur system and FlowJo software 
(ver.7.6.1).
Statistical analysis
In this study, data are expressed as mean ± SD. Statisti-
cal analysis was performed using student’s t-test and 
one-way ANOVA with Tukey posthoc analysis. Statisti-
cal analyses were done using GraphPad InStat software 
(Version 8.0.2). P values ≤ 0.05 were considered statisti-
cally significant. Statistical difference between groups is 
indicated by brackets as follows *p < 0.05, **p < 0.01, and 
***p < 0.001.
Results
Flow cytometry analysis confirmed typical CSCs phenotype
To enrich CSCs, we performed MACS analysis using 
specific antibodies against the surface  CD133+ marker. 
Flow cytometry was done to confirm the purity of iso-
lated CSCs post-MACS. According to our data, about 
90 ± 2.4% of isolated cells were CD133 positive, show-
ing that a large proportion of isolated cells exhibited a 
CSC-like phenotype (Fig. 1a). These data showed the suc-
cessful identification and isolation of the  CD133+ CSCs 
subpopulation from the HT-29 cell line.
Inhibition and stimulation of LXR modulated CSCs viability 
in a dose‐dependent manner
CHOL content and lipid synthesis are pivotal factors 
to maintain dynamic growth in cancer cells. In sup-
port of this claim, the modulation of LXR could affect 
CSCs survival and growth [16]. The modulatory effect 
of T0901317 and SR9243 was studied on  CD133+ CSCs 
using MTT assay. Data showed reduced CSCs survival 
rate after incubation with T0901317 (an LXR ligand), and 
SR9243 (an LXR antagonist) in a dose-dependent man-
ner (Fig.  1c and e). Compared to control CSCs, ~ 2.5-
fold decrease was obtained in the survival rate of CSCs 
exposed to 5 µM T0901317, and this value reached ~ 5.0-
fold in the group treated with 200  µM T0901317. After 
48-hour incubation of  CD133+ CSCs with different doses 
of T0901317, the  IC50 value was ~ 5 µM (Fig. 1c). Simi-
lar to results from T0901317-treated CSCs, we found 
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a ~ 2.1-fold decrease in the survival rate of CSCs exposed 
to 25  nM SR9243 and this value reached ~ 4.5-fold in 
the group received 200 nM SR9243 (Fig. 1e). The results 
showed an  IC50 value of ~ 69 nM for CSCs treated with 
SR9243. We selected  IC50 values for subsequent analyses.
LXR activation modulated the expression of ABC 
transporters
ABC transporters participate in lipid efflux and cell 
resistance against osmotic pressure [17, 18]. The mRNA 
expression and protein levels of ABC transporters were 
studied by RT-qPCR and western blotting after treatment 
with LXR agonist T0901317. Data revealed that the incu-
bation of CSCs with 5 µM T0901317 for 48 h increased 
significantly the expression of ABCA1 (p < 0.05), ABCG5 
(p < 0.01). Despite the induction of ABCG8 expression in 
comparison with the control group, the changes did not 
reach statistical significance (p > 0.05) (Fig.  2a). West-
ern blotting showed a statistically significant increase of 
ABC proteins in the group that received 5 µM T0901317 
Fig. 1 a CD133+ CSCs were enriched from human HT‑29 cell line using MACS and the purity of isolated cells assessed by FITC‑conjugated 
anti‑CD133 antibody and flow cytometry analysis. b The chemical structure of T0901317. c Measuring CSCs survival after exposure to various 
concentrations of T0901317 (5–200 µM) using MTT assay. d The chemical structure of SR9243. e CSCs survival rate was also measured after 
treatment with SR9243 (25–200 nM) using MTT assay. Data confirmed a dose‑dependent activity of T0901317 and SR9243 on HT‑29‑isolated CSCs
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compared to the control group (p < 0.05) (Fig. 2b). Inter-
estingly, we found that the protein level of the LXR 
receptor was also increased in CSCs exposed to 5  µM 
T0901317 after 48 h. Commensurate with these com-
ments, 48-hour incubation of CSCs with LXR agonist 
could increase ABC transporter gene expression and pro-
tein synthesis.
Activation of LXR increased CSCs sensitivity to hypo‐
osmotic stress
To decipher the possible effect of LXRs activation on 
CSCs resistance to hypo-osmotic stress, we measured 
the changes in CSCs diameter after treatment with 5 µM 
T0901317 in hypotonic condition. The cell size was mon-
itored at different time points 15, 30, and 45 min. Bright-
field microscopic imaging showed the changes in CSCs 
diameter after treatment with 5  µM T0901317 under 
hypo-tonic conditions (Fig. 2c). It was found that hypo-
tonic conditions caused a more rapid cell swelling rate 
in T0901317-treated CSCs as compared with the control 
group (p < 0.05) (Fig. 2d). The mean change of cell diam-
eter was not statistically significant in the control group 
over time (Fig. 2d).
LXR activation inhibited the CSCs proliferation 
and clonogenic potential
The high level of intracellular CHOL activates LXR tran-
scriptional and contributes to an increased CHOL efflux, 
reduction of CHOL influx, and synthesis [10]. IF imaging 
revealed that the activation of LXR in CSCs reduced the 
fluorescence intensity of the Ki67 antigen (a nuclear pro-
liferation factor) compared to the control group (Fig. 3a). 
Taken together, these results indicated that LXR activa-
tion reduced the CSCs proliferation rate in vitro.
To further assess the possible effect of LXR activation 
on the clonogenic capacity of CSCs, cells were cultured 
in 3D soft agar after being treated with 5 and 10  µM 
T0901317. Based on data, the incubation of CSCs with 
the LXR activator inhibited the number of colonies after 
48 h (Fig.  3b). No significant differences were observed 
between the number of  CD133+ CSCs in groups 5  µM 
and 10  µM T0901317 groups (p > 0.05) (Fig.  3b). Taken 
together, these data showed that activation of the LXR 
receptor inhibited clonogenic capacity and malignancy.
LXR activation reduced CSCs migration and invasion
Transwell migration assay showed that the treatment 
of CSCs with 5 and 10  µM T0901317 significantly sup-
pressed the migration of  CD133+ CSCs after 48 h com-
pared to the non-treated CSCs (p < 0.001; Fig.  3c). 
However, no significant differences were observed 
between the number of migrated CSCs treated with 5 
and 10  µM T0901317 (p > 0.05; Fig.  3a). Scratch assay 
showed that the treatment of CSCs with 5 µM T0901317 
decreased the distance between scratch edges compared 
to the control CSCs but these values did not reach sta-
tistically significant differences (Fig.  3d). These results 
indicated that the activation of LXR suppressed CSCs 
migration and invasion.
Inhibition of LXR reduced glycolysis/lipogenesis 
and hypoxia factor in CSCs
CSCs metabolism and survival are associated with glyco-
lysis and lipogenesis [4]. Here, we investigated whether 
LXR inhibition using SR9243 could alter the expression 
of enzymes associated with the Warburg effect (PFKFB3 
and GSK3β) and lipogenesis (SCD1 and FASN). Here, 
we showed that incubation of CSCs with 60 nM SR9243 
downregulated the expression of PFKFB3 (p < 0.0001), 
GSK3β (p < 0.01), and HIF-1α (p < 0.05) compared to 
non-treated CSCs. Calling attention, the expression of 
SCD1 and FASN were not changed in CSCs after being 
with 60 nM SR9243 (p > 0.05; Fig. 4a). Western blot anal-
ysis results confirmed real-time PCR results. Despite the 
reduction of SCD, FASN, LXR protein levels, the changes 
did not reach statistically significant levels (Fig.  4b). 
According to our data, protein levels of HIF-1α, GSK3β, 
PFKFB3 were significantly diminished upon treatment 
with 60  nM SR9243 after 48 h. These data showed that 
LXR inhibition could decrease the expression and pro-
tein levels of factors associated with lipolysis, hypoxia, 
and glycolysis.
LXR inhibition reduced ROS content and clonogenic 
capacity
We investigated ROS content by using DCFH-DA assay 
after inhibition of LXR with 60  nM SR9243. Compared 
to the control CSCs, increased fluorescence intensity was 
indicated in SR9243-treated CSCs, showing that the inhi-
bition of LXR in CSCs resulted in the accumulation of 
Fig. 2 Effect of LXR agonist (T0901317) on the ABC transporter gene expression and protein levels LXRs in CSC. a mRNA expression levels of ABCA1, 
ABCG5, and ABCG8 levels were determined by RT‑PCR after incubation of the treatment group with 5 µM T0901317 for 48 h. b Protein levels of 
ABCA1, ABCG5, ABCG8, and LXRs were determined by western blotting. CSCs were treated with 5 µM T0901317 for 48 h. Measuring CSCs resistance 
to hypo‑osmotic stress after treatment with LXR agonist. c Changes in diameter of CSCs were recorded after exposure to 5 µM T0901317 every 
15 min over 45 min (n = 60). d CSC diameter was increased in treated groups compared to the control group. All experiments were performed in 
triplicate and data were expressed as mean ± SD. Tukey posthoc analysis. *p < 0.05, **p < 0.01, and ***p < 0.001
(See figure on next page.)
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ROS after 48 h (p < 0.05; Fig. 5a). We found that 48-hour 
incubation of CSCs with 60 and 120  nM SR9243 pro-
foundly diminished the colony formation capacity in 
a 3D soft agar compared to the non-treated control 
CSCs (p < 0.001; Fig. 5a). No significant differences were 
observed between the number of CSC colonies in groups 
received 60 and 120 nM SR9243 (p > 0.05; Fig. 5a).
The modulation of LXR promoted apoptosis in CSCs
To this end, CSCs were exposed to LXR agonist (5  µM 
T0901317) and antagonists (60  nM SR9243) for 48 h 
(Fig. 5b). Based on the obtained data, the inhibition and 
stimulation of the LXR receptor could increase the per-
cent of CSCs entering apoptosis after 48 h, indicated by 
an elevation in the number of Annexin-V positive CSCs. 
It seems that the inhibition of LXR had superiority to 
Fig. 3 Measuring CSCs proliferation using Ki‑67 factor (a) and clonogenic capacity after LXR activation (b). The fluorescence intensity of Ki‑67 in 
CSCs with or without 5 µM T0901317 was analyzed by IF. CSCs were directly labeled using the PE‑conjugated anti‑Ki‑67 antibody. b The number of 
colonies was decreased in after treatment with 5 and 10 µM T0901317 compared to the control group. The incubation of CSCs with T0901317 at 
both doses 5 and 10 µM did yield statistically significant differences (p > 0.05). Effects of LXR activation on migration and invasion CSCs after 48 h (c 
and d). CSCs were treated with 5 and 10 µM T0901317 and the number of migrated CSCs and invasion rates were evaluated by Transwell migration 
and scratch assays. c Transwell assays showed that the treatment of CSCs with 5 and 10 µM T0901317 decreased the number of migrated CSCs 
compared with the control (p < 0.001). d Scratch assay showed that the distance of scratch edges increased upon treatment with 5 µM T0901317 
compared to the control group. However, the values did not reach statistically significant results. Student t‑test and One‑Way ANOVA with Tukey 
posthoc analysis. ∗p < 0.05, ∗∗p < 0.01, and ∗∗∗p < 0.001
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induce apoptosis compared to the group that received an 
LXR stimulator.
Discussion
The main reason for the failure of CRC treatment could 
be explained by the presence of CSCs which possess the 
characteristics of self-renewal, tumorigenicity, metasta-
sis, and metabolism heterogenicity [2]. Thus, the iden-
tification of CSCs at the molecular level will allow us to 
detect metastasis earlier and provide new opportunities 
for drug development.
The current experiment was a preliminary study to 
address the modulation of LXR on the dynamic growth 
of CSCs. Here, we showed that the activation of LXR 
T0901317 reduced the viability and proliferation of 
CSCs after 48 h. Consistent with our data, it has been 
shown that the stimulation of LXR could down-regulate 
β-catenin targets such as Bmp4, Myc, Cyclin D1, and 
Mmp7 participating in the survival and proliferation 
of colon cancer cells [19]. The effect of LXR activity on 
CSCs proliferation could be explained by this finding that 
LXR could downregulate SCARB1 gene encoding scav-
enger receptor B1 (SR-B1) [20]. Indeed, SR-B1 promotes 
CHOL uptake from the body and induces cell growth, 
and even promotes tumor progression or metastasis [21]. 
Thus, LXR activation could be resulted in SR-B1 suppres-
sion and CHOL starvation in CSCs as well as reduced 
their proliferation.
Based on our data, the promotion of LXR significantly 
induced ABC-A1/G5/G8 expression in CSCs, which con-
firms the results of studies conducted by Yu [22], and 
Repa [23]. They showed that LXR activation resulted in 
ABC-G5/G8 mRNAs overexpression and CHOL efflux 
from hepatocytes and enterocytes. In contrast, signifi-
cant downregulation of the LXR and ABCB1 in the early 
stage of CRCs is associated with the accumulation of 
CHOL within tumor cells, and subsequently promotes 
the initial phase of CRCs development [24]. In support of 
our data, the stimulation of LXR in CSCs increased ABC 
transporters, leading to tumoricidal effects on CSCs. In 
hypercholesterolemia condition, the promotion of LXR 
followed by increased ABC efflux activity, and CHOL 
efflux to protect enterocytes from sterol accumulation 
[22, 25, 26]. Therefore, the up-regulation of ABC trans-
porters can reduce CHOL content and tumorigenicity of 
CSCs.
Besides their roles in lipid metabolism, ABC transport-
ers control the normal cell size by the release of cellular 
ions and loss of water via a regulatory volume decrease 
or volume-regulated anion channel [27]. In this study, 
Fig. 4 Effect of SR9243 on metabolic LXR‑targets genes in CSCs. a mRNA expression levels of PFKFB3, GSK3β, SCD1, FASN, and HIF‑1α were 
determined by real‑time PCR after incubation with 60 nM SR9243 over 48 h. b Protein levels of PFKFB3, GSK3β, SCD1, FASN, HIF‑1α, and LXRs were 
determined by western blotting in CSCs after incubation with 60 nM SR9243. All experiments were performed in triplicate and data were expressed 
as mean ± SD. Student t‑test. *p < 0.05, **p < 0.01, and ***p < 0.001
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we found that the activation of LXR is closely related 
to the function of ABC transporters in which the mean 
CSC diameter increased in early 15 minutes incubated 
in hypo-osmotic conditions. The reduced CSCs survival 
rate coincided with increased cell size showed that CSCs 
lost the capacity to resist osmotic stress. The activation of 
ABC transporters after LXR stimulation showed a com-
pensatory response under hypotonic conditions. Under 
hypo-osmotic conditions, LXR could induce ABCA1 
expression and CHOL depletion by the activation of RVD 
to protect CSCs from osmotic stress.
The activation of LXR seems to decrease CSCs tum-
origenesis which is associated with colony formation 
capacity. Previously, it was shown that LXR could sup-
press the clonogenic capacity of CSCs via inhibiting 
the Hedgehog-Wnt signaling pathway which maintains 
CSC survival and self-renewal ability [28, 29]. Moreo-
ver, CHOL biosynthesis is essential for CSCs propaga-
tion [30], and mammosphere formation [31], that its 
synthesis is negatively regulated by LXR activity, and 
hence inhibited the CSC colony formation.
The activation of LXR seems to decrease the CSCs 
invasion and migration. These results could be related 
to the role of CHOL is an important component of 
membrane lipid rafts containing the signaling mol-
ecules precipitating in cell migration [16, 32, 33]. 
Moreover, ABCA1 modulates CHOL distribution in 
the membrane which affected the pathways promoting 
cell migration [9]. Therefore, any change in the com-
position of the CSC membrane could be linked to the 
Fig. 5 Representative image of ROS assay and colony formation capacity CSCs after being‑treated with SR9243 (a). DCFH‑DA assay showed an 
increase of fluorescence intensity in CSCs after exposure to 60 nM SR9243, indicating increased ROS content after LXR inhibition. The number 
of colony formation was calculated in in 3D soft agar after LXR inhibition. Data showed a statistically significant level between the control and 
treatment groups. Measuring the percent of apoptotic CSCs after‑being treated with SR9243 and T0901317 (b). CSCs were incubated with LXR 
agonist (5 µM T0901317) and antagonists (60 nM SR9243) for 48 h. Student t‑test and One‑Way ANOVA with Tukey posthoc analysis. *p < 0.05, 
**p < 0.01, and ***p < 0.001
Page 11 of 13Dianat‑Moghadam et al. Cancer Cell Int          (2021) 21:100  
downstream pathways which influenced the CSCs pro-
liferation, clonogenicity, and migration. Based on our 
data, the promotion of LXR significantly induced apop-
tosis in CSCs, which could be explained based on pre-
viously published data, LXRs induced cell cycle arrest 
via caspase-dependent activity in HT-29 cells in a xeno-
graft model [34].
On the other hand, in comparison with differentiated 
CRC cells,  CD133+CR-CSCs favor glycolysis and lipo-
genesis [35], which provide potential metabolic targeting 
for CR-CSCs treatment. We found that inhibition of LXR 
activity altered the expression of PFKFB3, GSK3β, FASN, 
and SCD1, the critical key enzymes in the control of gly-
colysis and lipogenesis, and thus resulted in the reduction 
CSCs growth and proliferation. All of the four enzymes 
promote the progression of the tumor and are directly 
upregulated by LXRs in human somatic tumor cells [12]. 
Lipogenesis genes in this study, however, have shown less 
reduction, which may duo to the  CD133+ CR-CSC cells 
have favored active glycolysis more than lipogenesis [35]. 
HIF-1α induces the expression of glycolytic genes [36], and 
we found the inhibition of LXR activity reduced HIF-1α 
expression. This result is inconsistent with a previous 
study that has reported the suppression of LXR inhibited 
HIF-1α and enzymes associated with glycolysis [37].
The metabolism of cancer cells and pluripotent stem 
cells rely on the Warburg effect to minimize ROS produc-
tion [38]. Our data showed that LXR inhibition reduced 
Warburg effect-associated enzymes, and thus, the ROS 
levels were increased after LXR suppression. Notably, the 
inhibition of SCD1 [39], and PFKFB3 [40] can induce the 
ROSs generation in neoplastic cells. FASN and the low 
ROSs niche participate in the maintenance of stemness 
and the self-renewal capacity of CSCs [41] [11]. Therefore, 
upon treatment of CSCs with LXR antagonist SR9243, we 
found increased ROS content and reduced FASN which 
could hamper the clonogenic capacity. Besides ROS ele-
vation, the increase of apoptosis could be related to, and 
PFKFB3 which later acts as an inducer of p27 degradation 
and cell cycle progression, hence, its silencing is found to 
arrest cells at G1/S and induces apoptosis [42]. In sum-
mary, SR9243 suppresses the expression of metabolic acti-
vator enzymes, and hence inhibits the cell clonogenicity 
and metabolism, and induces apoptosis in  CD133+ CSCs 
in vitro. There are some limitations in this study that are 
associated with the lack of different CSC types from mul-
tiple cell lines. Treatment of different CSC types with LXR 
agonist/antagonist could help us to find possible differ-
ences in the function of LXR in several CSCs. Also, future 
studies must focus to find any relationship of LXR signal-
ing with resistance mechanisms in CSCs.
Conclusions
Here, we showed the modulation of LXR could alter the 
activity of CSCs in vitro. It seems that the LXR signaling 
pathway is closely correlated with different CSC bioac-
tivities such as migration, glycolysis, lipogenesis, cell sur-
vival, and osmotic stress. However, more investigations 
are highly demanded to address the critical role of the 
LXR pathway on different CSC types.
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